Cargando…

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

BACKGROUND: Randomized trials evaluating programmed cell death protein 1 (PD-1) inhibitors in metastatic melanoma either permitted treatment for 2 years (pembrolizumab) or more (nivolumab). The optimal duration of therapy is currently unknown due to limited data, and shorter therapies may be effecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pokorny, Rebecca, McPherson, Jordan P, Haaland, Benjamin, Grossmann, Kenneth F, Luckett, Carolyn, Voorhies, Benjamin Newell, Sageser, Daniel S, Wallentine, Jocelyn, Tolman, Zachary, Hu-Lieskovan, Siwen, Swami, Umang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843310/ https://www.ncbi.nlm.nih.gov/pubmed/33500258 http://dx.doi.org/10.1136/jitc-2020-001781

Ejemplares similares

The dark side of immunotherapy
por: Okwundu, Nwanneka, et al.
Publicado: (2021)

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
por: Hamid, Omid, et al.
Publicado: (2022)

Response to high dose ipilimumab plus temozolomide after progression on standard or low dose ipilimumab in advanced melanoma: a retrospective analysis
por: Williamson, Julie, et al.
Publicado: (2023)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome
por: Marsiglio, John, et al.
Publicado: (2023)

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2021)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
por: Larroquette, Mathieu, et al.
Publicado: (2022)

PD1 blockade enhances K(+) channel activity, Ca(2+) signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer
por: Newton, Hannah S, et al.
Publicado: (2020)

First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma
por: Wang, Xuechen, et al.
Publicado: (2021)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
por: Kurino, Taiki, et al.
Publicado: (2020)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
por: Wagner, Michael J, et al.
Publicado: (2021)

Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)
por: Vavolizza, Rick D, et al.
Publicado: (2022)

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study
por: Elkrief, Arielle, et al.
Publicado: (2023)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2020)

Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer
por: Zhang, Puran, et al.
Publicado: (2022)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
por: Ghonim, Mohamed A, et al.
Publicado: (2021)

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
por: Wolfson, Benjamin, et al.
Publicado: (2021)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study
por: Das, Anirban, et al.
Publicado: (2022)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
por: Homicsko, Krisztian, et al.
Publicado: (2023)

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
por: Swami, Umang, et al.
Publicado: (2019)

Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia
por: Shahid, Sanam, et al.
Publicado: (2023)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

MDR1-EXPRESSING CD4(+) T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE
por: Di Roio, Anthony, et al.
Publicado: (2023)

IMMU-29. AIF1 IS A PROGNOSTIC BIOMARKER AND CORRELATED WITH IMMUNE INFILTRATES IN GLIOMAS
por: Chai, Yi, et al.
Publicado: (2020)

IMMU-17. Comprehensive immunological gene expression profiling of pediatric brain tumors
por: Levine, Adrian, et al.
Publicado: (2022)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion
por: Le Gall, Camille, et al.
Publicado: (2022)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways
por: Cecil, Denise, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3m7b01pl27150a20a5i3n1kk7e